Amphastar: New FDA Approval Opens a Floodgate of Opportunities
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) recently announced that the U.S. Food and Drug Administration has granted approval of its New Drug Application (NDA) for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is...
